IRadimed Corporation
Price Action
Technical Summary
CONSOLIDATINGIRadimed Corporation is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 44), showing significant lag compared to the market leaders. Earnings growth of 22% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $89.47 | -3.61% | BELOW |
| 50 SMA | $95.57 | -9.77% | BELOW |
| 100 SMA | $97.25 | -11.32% | BELOW |
| 150 SMA | $92.40 | -6.66% | BELOW |
| 200 SMA | $86.50 | -0.30% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IRMD in an uptrend right now?
IRMD has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is IRMD overbought or oversold?
IRMD's RSI (14) is 38. The stock is in neutral territory, neither overbought nor oversold.
Is IRMD outperforming the market?
IRMD has a Relative Strength (RS) Rating of 44 out of 99. IRMD is currently lagging the broader market.
Where is IRMD in its 52-week range?
IRMD is trading at $86.24, which is 80% of its 52-week high ($107.90) and 62% above its 52-week low ($50.31).
How volatile is IRMD?
IRMD has a Beta of 0.85 and 52-week volatility of 36%. It's less volatile than the S&P 500 - generally more stable.